CDK9 — Drug Target

All drugs that target CDK9 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

CDK9 inhibitor · CDK inhibitor

Phase 3 pipeline (2)

• RO4917838 · Hoffmann-La Roche · CDK9 inhibitor · Oncology
  RO4917838 is a small molecule that targets the CDK9 protein.
• TPX-114 · Tego Science, Inc. · CDK inhibitor · Oncology
  TPX-114 is a small molecule inhibitor of the CDK9 enzyme.

Phase 2 pipeline (8)

• LY3832479 · Eli Lilly and Company · CDK9 inhibitor · Oncology
  LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).
• ASP8477 · Astellas Pharma Europe B.V. · CDK inhibitor · Oncology
  ASP8477 is a small molecule that targets the CDK9 protein.
• BAY2253651 · Bayer · CDK9 inhibitor · Oncology
  BAY2253651 is a small molecule that targets the CDK9 protein.
• ASP0456 · Astellas Pharma Inc · CDK9 inhibitor · Oncology
  ASP0456 is a small molecule inhibitor of the CDK9 enzyme.
• CST-3056 · CuraSen Therapeutics, Inc. · CDK9 inhibitor · Oncology
  CST-3056 is a small molecule inhibitor of the CDK9 enzyme.
• CAL02 · Eagle Pharmaceuticals, Inc. · CDK9 inhibitor · Inflammation
  CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.
• LY3838915 · Eli Lilly and Company · CDK9 inhibitor · Oncology
  LY3838915 is a small molecule that targets the CDK9 protein.
• DYV700 · Dyve Biosciences, Inc. · CDK inhibitor · Oncology
  DYV700 is a small molecule inhibitor of the CDK9 enzyme.